With no approved therapies for NRG-1 cancers, zenocutuzumab offers a promising treatment option for this patient population. Zenocutuzumab (MCLA-128) had anti-tumor properties in multiple advanced, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback